Only in Titles

           Search results for: Human CA15-3 ELISA ELISA    

paperclip

#28447743   // Save this To Up

Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.

The present study aimed to investigate the binding of circulating mucin 1 (MUC1) antibody with serum MUC1 antigen in stage IV breast cancer. Serum samples of 61 patients with stage IV breast cancer and 64 patients with early-stage breast cancer were collected. The anti‑MUC1 antibody (IgG) and MUC1 antigen (cancer antigen 15‑3; Ca15‑3) were detected using an indirect enzyme-linked immunosorbent assay (I‑ELISA) and ELISA, respectively. The MUC1 IgG affinity was detected using a urea degradation combining ELISA. Western blot analysis and an inhibition test were performed for verification of the binding of anti‑MUC1 IgG with MUC1 antigen, and their correlation was analyzed. The results showed that there was a negative correlation between anti‑MUC1 IgG and CA15‑3 antigen in stage IV breast cancer when positive CA15‑3 antigen and/or anti‑MUC1 IgG were selected (r=‑0.417; P=0.0044). The positive anti‑MUC1 IgG with positive Ca15‑3 antigen was more common in stage IV breast cancer, compared with early‑stage breast cancer (χ2=4.629; P=0.031), however, Ca15‑3 antigen positivity was higher in stage IV breast cancer, compared with early‑stage breast cancer (χ2=10.58; P=0.001). Anti‑MUC1 IgG was able to bind to the MUC1 antigen in stage IV breast cancer. No differences in the 8R-MUCPT inhibition ratio were found between the two groups (P=0.778), and there were no differences in the affinity of anti‑MUC1 IgG (P=0.873). In stage IV breast cancer, circulating anti‑MUC1 antibody was found to bind serum MUC1 antigen, although their compatibility was low. No significant difference was found in the affinity of the anti‑MUC1 antibody between stage IV breast cancer and early‑stage breast cancer.

1575 related Products with: Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.

Breast cancer and matched Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast adjacent normal ti

Related Pathways

paperclip

#25531720   // Save this To Up

Analysis of the discriminative methods for diagnosis of benign and malignant solitary pulmonary nodules based on serum markers.

Screening indexes of tumor serum markers for benign and malignant solitary pulmonary nodules (SPNs) were analyzed to find the optimum method for diagnosis.

1785 related Products with: Analysis of the discriminative methods for diagnosis of benign and malignant solitary pulmonary nodules based on serum markers.

Tissue array of ovarian g PSA test card, serum , Ca Troponin I test card, ser Myoglobin test card, seru Bovine Androstenedione,AS Rat Forkhead Box P3(FOXP3 MarkerGeneTM Fluorescent Ofloxacin CAS Number [824 Malignant melanoma, metas Malignant melanoma, metas Multiple tumor tissue arr Cellufine Formyl , 50 ml

Related Pathways

paperclip

#21622132   // Save this To Up

Optimal cut-off values for tumor markers in cerebrospinal fluid with ROC curve analysis.

To select optimal cut-off values of tumor markers in cerebrospinal fluid for the diagnosis of meningeal carcinomatosis, the concentrations of CEA, CA125, CA153, CA199, CA724, CYFRA21-1, AFP and NSE were determined by means of double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) in 21 MC patients, 25 cancer patients without leptomeningeal disease (group one) and 45 meningitis patients (group two) using the Roche E170 modular immunoassay analyzer. Optimal cut-off values were selected based on a receiver-operating characteristic curve. The results showed that CA125 and CEA in CSF were optimal diagnostic indices distinguishing between MC patients and cancer patients without leptomeningeal disease. Cut-off values for CA125 and CEA were 1.715 microliters and 0.274 microgram/l, respectively. In addition, CEA in CSF was the optimal diagnostic index distinguishing MC patients from meningitis patients. The cut-off value for CEA was 4.522 microgram/l.

1793 related Products with: Optimal cut-off values for tumor markers in cerebrospinal fluid with ROC curve analysis.

(7’-Benzyloxy-indolymet Multiple organs tumor and Multiple organ tumor and Bone marrow tumor and adj Breast cancer tissue arra Breast tumor survey tissu Breast tumor survey tissu Breast tumor survey tissu Breast tumor survey tissu Breast tumor survey tissu Breast tumor survey tissu Breast tumor survey tissu

Related Pathways

paperclip

#19269710   // Save this To Up

Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.

Previous studies have suggested aberrant expression of membrane B7-H3 in tumor cells. This aim of the study was to determine the expression level of soluble B7-H3 (sB7-H3) in circulation and to subsequently evaluate the clinical significance of circulating B7-H3 in patients with non-small cell lung cancer (NSCLC). The level of circulating B7-H3 was determined with ELISA and its correlation with the clinical data was examined. Receiver operating characteristic (ROC) curve analysis was performed to compare the sensitivity and specificity in the diagnosis of NSCLC. Circulating B7-H3 levels in patients with NSCLC were significantly higher than those in patients with other pulmonary diseases (OPD, p<0.001), or those in healthy volunteers (p<0.001). Using a cutoff of 30ng/ml, the sensitivity and specificity of sB7-H3 in differentiating between patients with NSCLC and patients with OPD, and between patients with NSCLC and healthy volunteers was, 48.8 and 98.5%, and 48.0 and 93.7%, respectively. Additionally, higher levels of sB7-H3 were associated with higher tumor stage, tumor size, nodal metastasis, and distant metastasis, but not with sex, age or histological subtype. An area under the curve (AUC) for all stages of NSCLC resulting from sB7-H3 (0.862), which was significantly better than any other tumor markers tested including CA125 (0.621), CA153 (0.571), CA199 (0.459), and CEA (0.638). These results suggest circulating B7-H3 is a valuable biomarker for NSCLC and an elevated level of circulating B7-H3 suggests a poor clinical character for NSCLC.

1457 related Products with: Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.

Lung non small cell cance Non-small cell lung cance Small cell lung carcinoma Non small cell lung carci Non small cell lung carci Lung small cell carcinoma High density non small ce Middle advanced stage lun Multiple lung carcinoma ( Lung cancer tissue array, Non small cell lung carci Non small cell lung carci

Related Pathways

paperclip

#12919909   // Save this To Up

[Clinical study of serum tissue polypeptide-specific antigen in breast cancer].

To investigate the expression of serum tissue polypeptide-specific antigen (TPS) in breast cancer patients and its clinical value in such cases.

1999 related Products with: [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].

Breast cancer and matched Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Late stage breast cancer Breast cancer and normal Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer and normal

Related Pathways

paperclip

#11956644   // Save this To Up

Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.

Cytosol of primary breast cancers from 217 women of predominantly Arab ethnicity were assayed for uPA, tPA, PAI-1 and a subset for ER, PR and pS2. Serum levels of CEA and CA153 were determined during follow-up. Only tPA correlated to nodal status and tumour grade, and PAI-1 to clinical stage. PAI-1 was related to uPA and both were inversely correlated with PR and pS2 (PAI-1 also to ER). Conversely tPA was directly correlated with ER, PR and pS2. Women with high tumour uPA and PAI-1, but not tPA, had shorter overall, and relapse-free, survival. Only nodal status and clinical stage were independent predictors in multivariate analysis. However, uPA and PAI-1 were more prognostically informative than ER or PR and their usefulness may extend to delineation of patients likely to respond to adjuvant therapy.

1650 related Products with: Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.

Breast cancer and matched Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Late stage breast cancer High density (188 cases 2 High density (188 cases 2 Breast cancer and normal Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra

Related Pathways